Eiger files for bankruptcy and will wind down operations after years of setbacks
Eiger BioPharmaceuticals said Monday morning that it filed for Chapter 11 protection in the United States Bankruptcy Court for the Northern District of Texas.
The Palo Alto, CA-based biotech also said Sentynl Therapeutics has inked a “stalking horse” agreement for its approved drug Zokinvy. If the court allows it, Sentynl could pay up to $26 million for the treatment. The drug was approved in 2020 for Hutchinson-Gilford progeria syndrome, an ultra-rare disease in which children age prematurely and have a short life expectancy of about 14 years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
